Hhdpharm Supply Gilteritinib Asp-2215 CAS 1254053-43-4 Pharmaceutical Apis Gilteritinib Powder

• Powder: Yes
• Customized: Non-Customized
• Suitable for: Adult
• Purity: >98%
• Color: White
• Grade: Pharmaceutical Grade
• Model NO.: HHD Pharm
• Transport Package: Alumininum Foli Bags
• Specification: 10g, 50g, 200g, 1kg, 5kg
• Trademark: hhdpharm
• Origin: China

Product Description

Wuhan HHD Supply Gilteritinib ASP-2215 CAS 1254053-43-4 Pharmaceutical APIs Gilteritinib Powder

 

Basic information:

 

Product Name:	ASP-2215
Synonyms:	ASP2215(Gilteritinib);ASP-2215;Gilteritinib;2-Pyrazinecarboxamide, 6-ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2H-pyran-4-yl)amino]-;6-Ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2H-pyran-4-yl)amino]-2-pyrazinecarboxamide;6-ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide;Gilteritinib (ASP2215)
CAS:	1254053-43-4
MF:	C29H44N8O3
MW:	552.71
Product Categories:	API

Boiling point	696.9±55.0 °C(Predicted)
density	1.242±0.06 g/cm3(Predicted)
storage temp.	-20°C
solubility	Soluble in DMSO (25 mg/ml)
form	solid
pka	14.39±0.50(Predicted)
color	Off-white to pale pink
Stability:	Stable for 1 year as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.

Description:

Gilteritinib is an inhibitor of FMS-related tyrosine kinase 3 (FLT3; IC₅₀ = 5 nM for the wild-type enzyme). It inhibits mutant forms of FLT3, including FLT3 with the internal tandem duplication mutation (FLT3-ITD), FLT3-ITD expressing the F691L mutation, and FLT3 with various tyrosine kinase domain mutations (FLT3-TKD; IC₅₀s =1.4-1.8, 12.2, and 0.7-2 nM, respectively). Gilteritinib also inhibits Axl and c-Kit with IC₅₀ values of 41 and 102 nM, respectively. It decreases the viability of blast cells isolated from patients with relapsed acute myeloid leukemia (AML) in a concentration-dependent manner. Formulations containing gilteritinib have been used in the treatment of AML.